TABLE 4.
Comparison of cardiotoxicity between crassicauline A and its converted products.
Compound | Dose (mg/kg) | VPB incubation period (s) | VT incidence (%) |
---|---|---|---|
Crassicauline A | 0.10 | 182.8 ± 84.58 | 100 |
Compound 1 | 0.10 | — | 0 |
Compound 2 | 0.10 | — | 0 |
Compound 4 | 0.10 | — | 0 |
“—”means that no arrhythmia occurred within 30 min after the administration of experimental compound. Data are expressed as mean ± S.D. (n = 10).